Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

Allogene Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic CAR T therapies for cancer, announced that the US FDA has granted ODD to ALLO-715 for the treatment of MM.